Dissolution testing is an in vitro technique of great importance in formulation and development of pharmaceutical dosage forms, as it can be used as a substitute for in vivo studies under strictly defined and specified conditions. The main objective of the present study is to conduct the comparative dissolution studies of various brands of same dosage forms and treatment of obtained dissolution data by using ƒ2 to determine whether all the formulations used were equivalent or significantly different. Five different brands of drug containing paracetamol and caffeine from different manufacturers were used in the study, and dissolution testing in different dissolution media viz., water, 0.1 N HCl, phosphate buffer of pH 4.5 and phosphate buffer of pH 6.8 was conducted for 12 tablets from each brand for 60 min. by using dissolution testing apparatus USP type-II. Samples were withdrawn at 10 min. time interval and analyzed for drug content by using HPLC technique. Percent drug release at each time interval was calculated for tablets and the data obtained were treated with statistical technique to meet the FDA requirements for obtaining a waiver of bioavailability and bioequivalence studies.
INTRODUCTION

Panadol
® Extra is indicated for the temporary relief of pain and discomfort associated with headache, tension headache, migraine headache, osteoarthritis, arthritis, cold and flu symptoms, toothache, dental procedures, muscular aches, sore throat, period pain and reduces fever. After oral administration, paracetamol is absorbed rapidly and completely from the gastrointestinal tract; peak plasma levels occur 10 to 60 minutes after administration. Paracetamol is uniformly distributed throughout most body fluids; the apparent volume of distribution is 1 to 1.2 L/kg. Paracetamol can cross the placenta and is excreted in breast milk. Plasma protein binding is negligible at usual therapeutic concentrations but increases with increasing concentrations. Caffeine is absorbed readily after oral administration. Maximal plasma concentrations are achieved in adults within one hour and the plasma half-life is about 3 to 7 hours.
Caffeine is almost completely metabolized in the liver by oxidation, demethylation and acetylation to various xanthine derivatives, which are excreted in the urine Panadol Extra and Panadol tablets are bioequivalent for AUC 0-10hr and C max for paracetamol. The extent of absorption (AUC) and peak plasma levels (C max ) of paracetamol were similar for Panadol ® Extra and Panadol tablets. The time to peak plasma level (t max ) was not significantly different (http://www.medicines.org.au/files/gcppextr. pdf). Paracetamol is N-(4-hydroxyphenyl) acetamide, with empirical formula C 8 H 9 NO 2 and has a molecular weight of 151.2 (Eur. Ph., 2008a) . Caffeine is 3,7-Dihydro-1,3,7-trimethyl-1H-purine-2,6-dione; with the empirical formula C 8 H 10 N 4 O 2 , and molecular weight of 194.2 (Eur. Ph., 2008b) .
Dissolution testing has become an essential tool in the pharmaceutical industry at various stages of development, manufacturing and marketing. For the comparison of dissolution profiles, similarity factor ƒ2 is gaining popularity due to its recommendation by various regulatory committees. Dissolution profiles are considered similar if the calculated ƒ2 value is between 50 and 100, this acceptance limit might not be correctly defined.
EXPERIMENTAL
Materials and reagents
All materials used in these investigations were of the highest purity available. They included standard grade paracetamol (PA) (Covidien/mallinchrodt Co. LTD USA) and caffeine (CA) (Sinochem, China), with purity of 99.60 and 99.20%, respectively. All these active ingredients were approved in-house working standard in October Pharma Co., 6 th October City, Egypt.
Methanol for isocratic chromatography, was obtained from Scharlua, Spain and ultrapure water was prepared using Direct Q Millipore and used to prepare the eluent and to dissolve standards. 
Dissolution Media
The four dissolution media employed were water, 0.1 N hydrochloric acid, phosphate buffer pH 4.5 and phosphate buffer pH 6.8. The preparations of 0.1 N hydrochloric acid, and phosphate buffer pH 6.8 were from USP (U.S.P, 2011a), while phosphate buffer pH 4.5 was prepared according to European pharmacopoeia (Eur. Ph., 2008c). These media were selected based on the FDA Guidance for Industry and the need to meet the criteria for biowaiver (FDA guidelines, 2000) .
Instruments and apparatus
Dissolution apparatus Model Sotax (Switzerland) type AT7 Code (CH-4008) and Varian dissolution apparatus Model VK7000 meet all the USP pharmacopeia requirements (type II paddle), Tablets Hardness tester (Pharma test Tablet testing system Model BT311E), pH meter WTW Inolab (Germany) instrument Model (D82362). Pharma test disintegration tester Model PTZ auto -2, HPLC Agilent model 1200 series, with auto sampler. 
Dissolution Method
Dissolution was carried out using Varian dissolution apparatus Model VK7000 and dissolution apparatus Sotax Model AT7 (Switzerland) digital tablet dissolution test apparatus II, with eight vessels of 1L capacity.
Dissolution of tablets was carried out in 12 vessels, each containing 900 mL of the dissolution media, at 100 rpm. The dissolution media were heated to 37±0.5 C. Three milliliter (3mL) samples were withdrawn at 10, 20, 30, 40, 50, and 60 minutes, and 3 mL of the media was replaced after each withdrawal. The concentration and quantity of the active pharmaceutical ingredients of each sample were determined using liquid chromatography (LC).
LC System
The HPLC system (Agilent model 1200, Germany) consists of separation module with solvent degasser, temperature controlled sample compartment and column heater, and a photodiode array detector. The UV detection was carried out at 210 nm. and a system control was used (Chemistation software) comprising data acquisition, and data processing system to calculate statistical analysis (Microsoft Excel 2007 professional Edition).
Chromatographic Conditions
LC separation was carried out using a HYPERSIL BDS C18 column (150 x 4.6 mm, and 5 µm particle size). All chromatographic experiments were performed in the isocratic mode. The used mobile phase consists of 0.02 mole L -1 tetrabutylammonium hydrogensulphate and methanol (100:45, v/v). The flow rate was set at 2 mL min -1 and the column was thermostated at 40 C with injection volume of 20 µL.
Standard solutions preparation 27.5 mg of PA was transferred to 50 mL volumetric flask; the PA standard was dissolved in about 40 mL of each of the four dissolution media separately. A 5 mL aliquot of CA stock standard solution containing 72.4 µg mL -1 was added to the PA volumetric flask, the volume was completed to the mark with each of the different dissolution media separately, and the finial concentration of PA and CA were 560.00 and 72.40 µg mL -1 respectively.
System suitability A system suitability test was an integral part of the development method to verify that the system is adequate for determination of the mentioned active ingredients. The suitability of the chromatographic system was demonstrated by comparing the obtained parameter values with the acceptance criteria of the ICH guideline (ICH guideline, 1995) .
A system suitability test of the chromatography system was performed before each validation run. Six replicate injections of a system suitability/calibration standard and one injection of a check standard were made. Figure 1 shows a typical chromatogram for PA, CA., peak area, retention time (Rt), tailing factor, asymmetry factor, and theoretical plates for the six suitability injections are reported in table 2. 
Data Analysis
The chemistation software was used to program the HPLC and to acquire and process the primary data. Microsoft Excel 2007 professional Edition was used to calculate the percent dissolved of the active pharmaceutical ingredients (APIs) for 12 individual tablets, and the mean and standard deviation were obtained. The similarity factor, ƒ2, was used to compare the dissolution profiles of the different products as required (FDA guideline, 1997) .
The difference factor (ƒ1) calculates the percent (%) difference between the two curves at each time point and is a measurement of the relative error between the two curves:
where n is the number of time points, Rt is the dissolution value of the reference batch at time t, and Tt is the dissolution value of the test batch at time t.
The similarity factor (ƒ 2 ) is a logarithmic reciprocal square root transformation of the sum of squared error and is a measurement of the similarity in the percent (%) dissolution between the two curves. For curves to be considered similar, ƒ 1 values should be close to 0, and ƒ 2 values should be close to 100. Generally, ƒ 1 values up to 15 (0-15) and ƒ 2 values greater than 50 (50-100) ensure sameness or equivalence of the two curves and, thus, of the performance of the test and reference products (FDA guideline, 1997).
RESULTS AND DISCUSSION
Evaluation of the physicochemical and pharmaceutical properties of tablets showed that all brands fulfilled the requirements of the USP and Eur. Ph. (Eur. Ph. 2008d , USP, 2011b , while each brand showed a significant difference in average weight, dimensions, hardness and disintegration time which corresponded to different mechanism of tablet processing, Table 3 shows physical and pharmaceutical properties of one brand and 4 generic tablets. ProntoPlus ® and Pandol* Extra have similarity in matching with Panadol ® Extra in average weight and disintegration time; also hardness test that give indication to the similarity in dissolution rate, where disintegration and hardness are effective factors in the dissolution rate. The dissolution rate of the active ingredient from a formulation is mainly related to the surface characteristics of the tablet. In contrast, the release rate of the active ingredient of Pyril ® Extra is lower than that observed for Panadol ® Extra and ProntoPlus ® in all the studied media, according to dissolution profile data. Water is often used as the dissolution medium, but is not always suitable for several reasons: the quality of water can varies depending on the source of water, the surface tension may be variable and depends on the types of excipients present in the formulation and the pH value is inherently difficult to measure because it can vary from day to day and may also change during the run depending on the active substance and excipients (U.S. Pharmacopeial Forum, 2004 The similarity of the dissolution profiles was determined using the similarity factor, ƒ2 (FDA guidelines, 1997). Two dissolution profiles are considered to be similar when the ƒ2 value is greater than 50 and dissimilar when less than 50 (FDA guidelines, 2000) . The ƒ2 was not determined for the comparison of products with more than 85% release of AIP in 15 min because they were established to be very rapidly dissolving. The only circumstance in which ƒ2 is not required according to the Guidance (FDA guidelines, 1997), is when 85% or more of the labeled amount of the drug dissolves in fifteen minutes. The ƒ2 values were calculated only up to the first point at which 85% release was achieved and at the 30-min time point. Subsequently, ƒ2 and ƒ1 factors were calculated to determine the similarity of Panadol ® * Extra with Panadol ® Extra in the four dissolution media; the reported data are considered as good evidence that Pandol* Extra is similar to innovator (Panadol ® Extra). 
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CONCLUSIONS
The differences in release characteristics among multisourced PA and CA tablets suggest likely implications for the bioavailability of the active ingredient, thus questioning the interchangeability of the products. Nevertheless, further advice would be needed to determine whether the observed in vitro differences are of any clinical significance. So that the in-vitro comparative dissolution was considered as indicating studies for determination the comparative dissolution between multi-sourced drugs with different formulations and strengths versus the reference drugs, and can be used as a substitute for in vivo studies under strictly defined and specified conditions. Our suggested study discusses the comparative dissolutions for multi-sourced PA and CA drugs with the reference ones. The study reached to the conclusion that Pandol* Extra (Locally manufactured) and ProntoPlus ® drugs are similar to the reference drug (innovator)
while Pyril ® Extra and Abimol ® Extra are dissimilar to the reference drug, due to Pyril ® Extra and Abimol ® Extra have different formulations and physical characteristics. This doesn't mean that Pyril ® Extra and Abimol ® Extra are not effective, but they must be subjected to in-vivo clinical study to give full reports. Table 8 shows summary of the obtained data to clarify the similarity ƒ2 and difference f1 factors in all cases.
